Jill Lacy MD

Associate Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Gastrointestinal Cancer Program

Medical Oncology

Education & Training

  • M.D., Yale University (1978)
  • Resident, Yale University School of Medicine , Internal Medicine  (1979 - 1982)
  • Fellow, Yale University School of Medicine , Oncology  (1982 - 1985)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Colorectal cancer; pancreatic cancer; esophageal cancer; gastric cancer; gall bladder cancer; anal cancer; biliary cancer; liver cancer; neuroendocrine tumors; brain tumors; non-Hodgkin's lymphoma (NHL); Hodgkin's disease; Kaposi's sarcoma


Cancers Treated

Anal, Brain, Colon (including Rectum), Esophagus, Gall Bladder, Gastrointestinal (including Stomach), Kaposi's Sarcoma, Pancreas, Unknown primary


Board Certifications

  • Internal Medicine, Board Certified (1982)
  • Medical Oncology, Board Certified (1991)

Clinical Trials

Conditions Study Title
Hepatocellular Carcinoma and Liver Multicenter, Placebo-Controlled, Randomized Pilot Study of the Effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and HCC Treated with Ablative Therapy and/or Transarterial Chemoembolization
Colorectal Cancer and Colon A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB 80702)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Stage IB Esophageal Cancer, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, and Esophagus A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma (RTOG 1010) {CIRB}
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer, Esophagus, and Stomach A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION

More Clinical Trials...

Edit Profile